

North Central Cancer Treatment Group

N027D A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation
Therapy in Glioblastoma Multiforme

Status Change – October 2, 2006

NOTICE OF STATUS CHANGE

This study is re-opening to Mayo (Jacksonville, Rochester, Scottsdale) and the University of Alabama at Birmingham at dose level 1 (50 mg/week CCI-779; 6000 cGy RT; 75 mg/m²/day TMZ) **effective October 2, 2006.**

Please retain this notice with the protocol.